Sander Slootweg to leave Replimune board at 2023 annual meeting

Replimune Group, Inc.

Sander Slootweg, founder/managing partner at Forbion, will not stand for reelection at the upcoming annual meeting.
Departure is not due to any dispute or disagreement with Replimune or its management.
Slootweg served as non-executive director since company's inception; CEO expresses gratitude for his service.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Sander Slootweg

Director

REPL · Replimune Group, Inc.

Filed: July 20, 2023, 7:59 PM ET

On July 14, 2023, Sander Slootweg, a member of the Board of Directors (the “Board”) of Replimune Group, Inc. (the “Company”), notified the Board that he will not stand for reelection at the Company’s 2023 annual meeting of stockholders (the “Annual Meeting”), and therefore his service as a director of the Company will end at the conclusion of the Annual Meeting.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sander Slootweg departed as Director at Replimune Group, Inc..

Action: will not stand for reelection
Role: Director

Exact text from the filing

On July 14, 2023, Sander Slootweg, a member of the Board of Directors (the “Board”) of Replimune Group, Inc. (the “Company”), notified the Board that he will not stand for reelection at the Company’s 2023 annual meeting of stockholders (the “Annual Meeting”), and therefore his service as a director of the Company will end at the conclusion of the Annual Meeting.

View on SEC.gov

Replimune Group, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-082566

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.